Effects of SGLT2 Inhibitors on Ion Homeostasis and Oxidative Stress associated Mechanisms in Heart Failure
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effects of SGLT2 Inhibitors on Ion Homeostasis and Oxidative Stress associated Mechanisms in Heart Failure
Authors
Keywords
Heart failure, SGLT2 inhibitors, Ion homeostasis, Oxidative stress, Inflammation, Fibrosis, Endothelial dysfunction
Journal
BIOMEDICINE & PHARMACOTHERAPY
Volume 143, Issue -, Pages 112169
Publisher
Elsevier BV
Online
2021-09-22
DOI
10.1016/j.biopha.2021.112169
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Pleiotropic Effects of SGLT2 Inhibitors
- (2021) Lee R. Goldberg JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Empagliflozin alleviates ethanol‐induced cardiomyocyte injury through inhibition of mitochondrial apoptosis via a SIRT1/PTEN/Akt pathway
- (2021) Ge Tian et al. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
- Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality
- (2021) Stefan J Schunk et al. EUROPEAN HEART JOURNAL
- Dapagliflozin reverses the imbalance of T helper 17 and T regulatory cells by inhibiting SGK1 in a mouse model of diabetic kidney disease
- (2021) Dan Wang et al. FEBS Open Bio
- Cardioprotection by SGLT2 Inhibitors—Does It All Come Down to Na+?
- (2021) Maximilian Trum et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPKα/TGF‐β/Smad signalling in type 2 diabetic rats
- (2021) Jingjing Tian et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis
- (2021) Gloria M. Gager et al. Frontiers in Cardiovascular Medicine
- Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
- (2020) M. Arow et al. Cardiovascular Diabetology
- Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure
- (2020) Nikole J. Byrne et al. Circulation-Heart Failure
- Chronic Empaglifozin treatment reduces myocardial infarct size in non-diabetic mice through STAT-3 mediated protection on microvascular endothelial cells and reduction of oxidative stress
- (2020) Panagiota Efstathia Nikolaou et al. ANTIOXIDANTS & REDOX SIGNALING
- Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: potential relevance to prevention of cardiovascular events
- (2020) Valentina Spigoni et al. Cardiovascular Diabetology
- Critical examination of mechanisms underlying the reduction in heart failure events with SGLT2 inhibitors: identification of a molecular link between their actions to stimulate erythrocytosis and to alleviate cellular stress
- (2020) Milton Packer CARDIOVASCULAR RESEARCH
- Are the benefits of SGLT2 inhibitors in heart failure and a reduced ejection fraction influenced by background therapy? Expectations and realities of a new standard of care
- (2020) Milton Packer EUROPEAN HEART JOURNAL
- Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice
- (2020) Byambasuren Ganbaatar et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Sodium–glucose cotransporters: Functional properties and pharmaceutical potential
- (2020) Ryuhei Sano et al. Journal of Diabetes Investigation
- Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment
- (2020) Ignatios Ikonomidis et al. Journal of the American Heart Association
- Myocardial ischaemia–reperfusion injury and cardioprotection in perspective
- (2020) Gerd Heusch Nature Reviews Cardiology
- Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium
- (2020) Donato Cappetta et al. PHARMACOLOGICAL RESEARCH
- Empagliflozin protects heart from inflammation and energy depletion via AMPK activation
- (2020) Chintan N. Koyani et al. PHARMACOLOGICAL RESEARCH
- Cardioprotective Effects of Sirtuin-1 and Its Downstream Effectors
- (2020) Milton Packer Circulation-Heart Failure
- SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials
- (2020) Faiez Zannad et al. LANCET
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin ameliorates renal oxidative stress and inflammation by stimulating AMPK–Akt–eNOS pathway in the isoprenaline-induced oxidative stress model
- (2020) Raquibul Hasan et al. Scientific Reports
- Oxidative Stress in Cardiovascular Diseases
- (2020) Emilie Dubois-Deruy et al. Antioxidants
- Molecular Nature and Physiological Role of the Mitochondrial Calcium Uniporter Channel
- (2020) B. Rita Alevriadou et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta‐analysis
- (2020) Javed Butler et al. ESC Heart Failure
- Delayed ischemic contracture onset by Empagliflozin associates with NHE-1 inhibition and is dependent on insulin in isolated mouse hearts
- (2019) Laween Uthman et al. CARDIOVASCULAR RESEARCH
- SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses
- (2019) Theodosios D. Filippatos et al. POSTGRADUATE MEDICINE
- SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
- (2019) Chenguang Li et al. Cardiovascular Diabetology
- Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease
- (2019) Hiddo J. L. Heerspink et al. DIABETOLOGIA
- Acute canagliflozin treatment protects against in vivo myocardial ischemia–reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation
- (2019) Alex Ali Sayour et al. Journal of Translational Medicine
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Endothelial Dysfunction in Chronic Heart Failure: Assessment, Findings, Significance, and Potential Therapeutic Targets
- (2019) Manal Alem INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Calcium Signaling in Cardiomyocyte Function
- (2019) Guillaume Gilbert et al. Cold Spring Harbor Perspectives in Biology
- Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction
- (2019) Nannan Zhang et al. Cardiovascular Diabetology
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of empagliflozin on brachial artery shear stress and endothelial function in subjects with type 2 diabetes: Results from an exploratory study
- (2019) Concetta Irace et al. Diabetes & Vascular Disease Research
- P6267Novel direct effects of SGLT2 inhibitor, Canagliflozin, on myocardial redox state in humans
- (2019) H Kondo et al. EUROPEAN HEART JOURNAL
- Role of endothelial dysfunction in heart failure
- (2019) Cinzia Zuchi et al. HEART FAILURE REVIEWS
- The SGLT2 Inhibitor Empagliflozin Ameliorates the Inflammatory Profile in Type 2 Diabetic Patients and Promotes an Antioxidant Response in Leukocytes
- (2019) Francesca Iannantuoni et al. Journal of Clinical Medicine
- Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells
- (2018) Chenke Xu et al. BIOCHEMICAL PHARMACOLOGY
- Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits
- (2018) Beatrice C. Lupsa et al. DIABETOLOGIA
- Interplay between ROS and Antioxidants during Ischemia-Reperfusion Injuries in Cardiac and Skeletal Muscle
- (2018) Tingyang Zhou et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms
- (2018) Sarah J. Mancini et al. Scientific Reports
- Diabetic patients with essential hypertension treated with amlodipine
- (2018) Agustin J. Ramirez et al. JOURNAL OF HYPERTENSION
- Dapagliflozin Attenuates Na+/H+ Exchanger-1 in Cardiofibroblasts via AMPK Activation
- (2018) Yumei Ye et al. CARDIOVASCULAR DRUGS AND THERAPY
- Treating oxidative stress in heart failure: past, present and future
- (2018) Atze van der Pol et al. EUROPEAN JOURNAL OF HEART FAILURE
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-inflammatory effects of empagliflozin in patients with type 2 diabetes and insulin resistance
- (2018) Sachiko Hattori Diabetology & Metabolic Syndrome
- Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts
- (2017) Tsung-Ming Lee et al. FREE RADICAL BIOLOGY AND MEDICINE
- AMPK: guardian of metabolism and mitochondrial homeostasis
- (2017) Sébastien Herzig et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Role of Nrf2 in Cardiovascular Function and Disease
- (2017) Sandro Satta et al. Oxidative Medicine and Cellular Longevity
- Platelets redox balance assessment: Current evidence and methodological considerations
- (2017) Anna Komosa et al. VASCULAR PHARMACOLOGY
- Empagliflozin Limits Myocardial Infarction in Vivo and Cell Death in Vitro: Role of STAT3, Mitochondria, and Redox Aspects
- (2017) Ioanna Andreadou et al. Frontiers in Physiology
- The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats
- (2017) Sebastian Steven et al. Redox Biology
- The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels
- (2016) Simon A. Hawley et al. DIABETES
- Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits
- (2016) Antonius Baartscheer et al. DIABETOLOGIA
- Mitochondrial function as a therapeutic target in heart failure
- (2016) David A. Brown et al. Nature Reviews Cardiology
- AMPK deficiency in cardiac muscle results in dilated cardiomyopathy in the absence of changes in energy metabolism
- (2015) Miranda M. Sung et al. CARDIOVASCULAR RESEARCH
- The Ins and Outs of Mitochondrial Calcium
- (2015) T. Finkel et al. CIRCULATION RESEARCH
- Prevention of oxidative stress, inflammation and mitochondrial dysfunction in the intestine by different cranberry phenolic fractions
- (2015) Marie-Claude Denis et al. CLINICAL SCIENCE
- Sodium-glucose cotransport
- (2015) Søren Brandt Poulsen et al. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- The Importance of NLRP3 Inflammasome in Heart Failure
- (2015) Brittany Butts et al. JOURNAL OF CARDIAC FAILURE
- Endothelial Dysfunction: Clinical Implications in Cardiovascular Disease and Therapeutic Approaches
- (2015) Kyoung-Ha Park et al. JOURNAL OF KOREAN MEDICAL SCIENCE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reciprocal regulation of TGF-β and reactive oxygen species: A perverse cycle for fibrosis
- (2015) Rui-Ming Liu et al. Redox Biology
- The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
- (2014) David ZI Cherney et al. Cardiovascular Diabetology
- Inhibiting Mitochondrial Na + /Ca 2+ Exchange Prevents Sudden Death in a Guinea Pig Model of Heart Failure
- (2014) Ting Liu et al. CIRCULATION RESEARCH
- Long-Term Treatment with the Sodium Glucose Cotransporter 2 Inhibitor, Dapagliflozin, Ameliorates Glucose Homeostasis and Diabetic Nephropathy in db/db Mice
- (2014) Naoto Terami et al. PLoS One
- The Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin Improves Diabetes-Induced Vascular Dysfunction in the Streptozotocin Diabetes Rat Model by Interfering with Oxidative Stress and Glucotoxicity
- (2014) Matthias Oelze et al. PLoS One
- Mechanisms of Altered Ca 2+ Handling in Heart Failure
- (2013) Min Luo et al. CIRCULATION RESEARCH
- Calcium cycling proteins and heart failure: mechanisms and therapeutics
- (2013) Andrew R. Marks JOURNAL OF CLINICAL INVESTIGATION
- NCLX: The mitochondrial sodium calcium exchanger
- (2013) Liron Boyman et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
- Intracellular Na+ and cardiac metabolism
- (2013) Johannes Bay et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
- Regulation of ATP production by mitochondrial Ca2+
- (2012) Andrei I. Tarasov et al. CELL CALCIUM
- Mitochondrial dysfunction in heart failure
- (2012) Mariana G. Rosca et al. HEART FAILURE REVIEWS
- The interaction of Ca2+ with sarcomeric proteins: role in function and dysfunction of the heart
- (2011) Hendrick E. D. J. ter Keurs AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
- Diabetic Downregulation of Nrf2 Activity via ERK Contributes to Oxidative Stress-Induced Insulin Resistance in Cardiac Cells In Vitro and In Vivo
- (2011) Y. Tan et al. DIABETES
- The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia
- (2011) R. A. DeFronzo et al. DIABETES OBESITY & METABOLISM
- Analysis of Na+/Ca2+ exchanger (NCX) function and current in murine cardiac myocytes during heart failure
- (2011) Lin Xu et al. MOLECULAR BIOLOGY REPORTS
- CaMKII in the Cardiovascular System: Sensing Redox States
- (2011) Jeffrey R. Erickson et al. PHYSIOLOGICAL REVIEWS
- Oxidative Stress and Diabetic Complications
- (2010) Ferdinando Giacco et al. CIRCULATION RESEARCH
- MCP-1, ICAM-1 and VCAM-1 are present in early aneurysmal dilatation in experimental rats.
- (2010) Jun Fan et al. FOLIA HISTOCHEMICA ET CYTOBIOLOGICA
- The role of Ca2+ signaling in the coordination of mitochondrial ATP production with cardiac work
- (2009) Robert S. Balaban BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS
- 8-hydroxy-2′ -deoxyguanosine (8-OHdG): A Critical Biomarker of Oxidative Stress and Carcinogenesis
- (2009) ATHANASIOS VALAVANIDIS et al. JOURNAL OF ENVIRONMENTAL SCIENCE AND HEALTH PART C-ENVIRONMENTAL CARCINOGENESIS & ECOTOXICOLOGY REVIEWS
- Mitochondrial Ca2+ and the heart
- (2008) E DEDKOVA et al. CELL CALCIUM
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started